EUCTR2009-015795-10-SI进行中（未招募）1 期
Assessing the safety and efficacy of switching to Azarga (Brinzolamide/Timolol Fixed Combination), as replacement therapy in patients with uncontrolled intraocular pressure - not applicable
Alcon d.o.o.0 个研究点目标入组 120 人开始时间: 2009年10月30日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients MUST meet the following conditions to qualify for enrollment into the study:
- •1.Must be at least 18 years of age.
- •2.Must have a clinical diagnosis of ocular hypertension, primary open-angle or pigment dispersion glaucoma in both eyes.
- •3.Must be on a stable regimen IOP lowering medication (either a single therapeutic agent or two separate ocular hypotensive agents) within 1 week of the Screening Visit.
- •4.Must have IOP considered to be safe (in the opinion of the investigator), in both eyes, in such a way that should assure clinical stability of vision and the optic nerve throughout the study period.
- •5.Must have an IOP of between 19 to 35 mmHg in at least one eye (with would be the study eye). In the eye that is not included in the study, the IOP should be able to be controlled on no pharmacologic therapy or on the study medicine alone.
- •6.Must be willing to discontinue the use of all other ocular hypotensive medications prior to receiving the study medication for the entire course of the study.
- •7.Must be able to follow instructions and be willing and able to attend all study visits.
- •8.Must have best corrected visual acuity of 6/60 (20/200 Snellen, 1.0 LogMAR) or better in each eye.
- •9.An Ethics Committee reviewed and approved (for use in this study) informed consent form must be read, signed, and dated by the participating patient, as well as signed and dated by the individual (Principal Investigator or other site personnel) obtaining the informed consent, before conducting the Screening Visit and prior to initiation of study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who meet any of the following conditions below will be excluded from this study:
- •1.Known medical history of allergy, hypersensitivity or poor tolerance to any components of the preparations to be used in this study that is deemed clinically significant in the opinion of the Principal Investigator.
- •2.Any abnormality preventing reliable applanation tonometry in either eye.
- •3.Corneal dystrophies.
- •4.Any opacity or patient uncooperativeness that restricts adequate examination of the ocular fundus or anterior chamber of either eye.
- •5.Concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye. Blepharitis or non-clinically significant conjunctival injection is allowed.
- •6.Intraocular conventional surgery or laser surgery in either eye that is less than three months prior to the Screening Visit.
- •7.Risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator’s best judgment.
- •8.Progressive retinal or optic nerve disease from any cause.
- •9.A history of, or at risk for uveitis or cystoid macular edema (CME).
- •10.History of ocular herpes simplex.
- •11.Use of systemic medications known to affect IOP (e.g., oral beta-adrenergic blockers, alpha-agonists and blockers, angiotensin converting enzyme inhibitors and calcium channel blockers), which have not been on a stable course for 7 days prior to Screening Visit or an anticipated change in the dosage during the course of the study.
- •12.Bronchial asthma or a history of bronchial asthma, bronchial hyper reactivity, or severe chronic obstructive pulmonary disease that would preclude the safe administration of a topical beta-blocker.
- •13.Sinus bradycardia (< 50 beats per minute), second- or third-degree atrioventricular block, sino-atrial block, overt cardiac failure, or cardiogenic shock that would preclude the safe administration of a topical beta-blocker.
- •14.Any clinically significant, serious, or severe medical or psychiatric condition.
- •15.Women of childbearing potential.
- •16.Women who are pregnant or lactating.
- •17.A condition, which in the opinion of the Principal Investigator, would interfere with optimal participation in the study, or which would present a special risk to the patient.
- •18.Participation in any other investigational study within 30 days prior to the Screening Visit.
研究者
相似试验
已完成
不适用
Investigation of efficacy and safety of switching from basal-bolus therapy to combination therapy with GLP-1 receptor agonist and basal insulin injection in type 2 diabetestype 2 diabetesJPRN-UMIN000013222Juntendo University Graduate School of Medicine30
尚未招募
3 期
B/F/TAF to DTG/3TC Switch StudyHIV/AIDSPACTR202404870570433niversity of Nairobi240
尚未招募
Unknown
Study of the effectiveness and safety of switching from JAK inhibitors to non-TNF biologics in elderly patients with rheumatoid arthritisRheumatoid arthritisJPRN-UMIN000050387Kawasaki Medical School30
招募中
1 期
Evaluating efficacy and safety of switching a boosted protease inhibitor to fostemsavir in PLWH with limited therapeutic options (FOST Switch)HIV-1MedDRA version: 20.1Level: LLTClassification code: 10020172Term: HIV infection NOS Class: 10021881CTIS2023-504192-25-00EAT ID Foundation60
进行中（未招募）
4 期
Evaluating efficacy and safety of switching HIV patients with limited further medicine choices from a particular type of HIV medicine (boosted protease inhibitor) to different type called fostemsavirHuman Immunological virus HIV-1 patients currently virologically supressed and being treated with with boosted protease inhibitorsInfections and InfestationsISRCTN10901519EAT ID60